People had fewer relapses with ZEPOSIA

  • ONE-YEAR STUDY

    48% fewer relapses with Zeposia vs a leading injectable medicine in a one-year study 48% fewer relapses with Zeposia vs a leading injectable medicine in a one-year study

    People taking ZEPOSIA had an ARR of
    0.181 vs 0.350 with a leading injectable.

  • TWO-YEAR STUDY

    38% fewer relapses with Zeposia vs a leading injectable medicine in a two-year study 38% fewer relapses with Zeposia vs a leading injectable medicine in a two-year study

    People taking ZEPOSIA had
    an ARR of
    0.172 vs 0.276
    with a leading injectable.

Annualized Relapse Rate (ARR) is the average number of relapses a group of people has in one year. A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).


More people were relapse free

  • ONE-YEAR STUDY

    78% of people were relapse free with Zeposia vs 66% of people who took a leading injectable medicine in a one-year study
  • TWO-YEAR STUDY

    76% of people were relapse free with Zeposia vs 64% of people who took a leading injectable medicine in a two-year study

A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448). A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).

A relapse was defined as new or worsening symptoms directly associated with MS that lasted more than twenty-four hours (after having a mostly stable neurological state for at least thirty days).

Disability progression
was also measured

When taking ZEPOSIA or Avonex 9 out of 10 people experienced no progression of physical disability. There was no significant difference in disability progression between people who took ZEPOSIA (7.6% of people) and those who took a leading injectable medicine (7.8% of people).

There was no significant difference
in disability progression between people who took ZEPOSIA (7.6% of people) and those who took a leading injectable medicine (7.8% of people).
Physical disability progression was measured every 3 months and combined from both studies.

Fewer new or enlarging lesions (T2) in both studies

T2 (lesions) refers to a type of
magnetic resonance imaging (MRI)
scan (a T2-weighted image) that can
be used to identify the total
number of lesions a person has.

  • ONE-YEAR STUDY

    48% fewer new or enlarging lesions (T2) with Zeposia vs a leading injectable medicine in a one-year study 48% fewer new or enlarging lesions (T2) with Zeposia vs a leading injectable medicine in a one-year study

    People taking ZEPOSIA had an average of
    1.47 lesions (T2) vs 2.84 with a leading injectable.

  • TWO-YEAR STUDY

    42% fewer new or enlarging lesions (T2) with Zeposia vs a leading injectable medicine in a two-year study 42% fewer new or enlarging lesions (T2) with Zeposia vs a leading injectable medicine in a two-year study

    People taking ZEPOSIA had an average of
    1.84 lesions (T2) vs 3.18 with a leading injectable.

A total of 895 people were in this study
(ZEPOSIA 447, a leading injectable 448).
A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).


Fewer lesions showing active inflammation (T1 Gd-enhancing)

T1 Gadolinium (Gd)-enhancing lesions are areas of active inflammation that show current MS activity in the brain.

  • ONE-YEAR STUDY

    63% fewer T1 Gd-enhancing lesions with Zeposia than a leading injectable medicine (in a one-year study) 63% fewer T1 Gd-enhancing lesions with Zeposia than a leading injectable medicine (in a one-year study)

    People taking ZEPOSIA had an average of 0.16 lesions (T1 Gd-enhancing) vs 0.43 with a leading injectable.

  • TWO-YEAR STUDY

    53% fewer T1 Gd-enhancing lesions with Zeposia than a leading injectable medicine in a two-year study 53% fewer T1 Gd-enhancing lesions with Zeposia than a leading injectable medicine in a two-year study

    People taking ZEPOSIA had an average of 0.18 lesions (T1 Gd-enhancing) vs 0.37 with a leading injectable.

A total of 895 people were in this study
(ZEPOSIA 447, a leading injectable 448).
A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).

Learn about ZEPOSIA safety & side effects

Once-daily oral dosing has held great appeal to my patients,
and I am pleased with the clinical results seen with ZEPOSIA."

— Edward J. Fox, MD, PhD
Director, Multiple Sclerosis
Clinic of Central Texas

About the clinical studies

In two separate clinical studies, a one-year and a two-year study, ZEPOSIA was compared to a leading injectable medicine, Avonex.

The two clinical studies, when combined, were one of the largest studies to compare one MS medication to another (not a placebo).

Together, the two studies included
1,769 people in total:

Each of the two clinical studies for ZEPOSIA was randomized, which means that participants were chosen randomly to receive either ZEPOSIA or a leading injectable medicine. The studies were also double-blind, so neither the professionals giving the medication nor the people taking it were told which medication was being administered.

Prior to joining the studies, all participants
had experienced at
least one relapse
within the past two years and had evidence ofT1 Gd-enhancing lesions.

T1 Gd-enhancing lesions are areas of active inflammation that show current MS activity in the brain.

The average age across both studies was

In both studies combined, approximately

Paid consultant of Bristol Myers Squibb.

Other areas to explore:

  • Learn about
    ZEPOSIA safety

    The safety of ZEPOSIA was evaluated in two separate clinical studies. Learn about the side effects that were reported.

    Side effects

  • A co-pay offer to help save§

    Eligible patients can receive a co-pay savings offer to help with the monthly cost of treatment.

    Enroll now

    §Program terms and eligibility criteria apply.

Important Safety Information

Collapse

Do not take ZEPOSIA if you:

  • have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months
  • have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker
  • have untreated, severe breathing problems during your sleep (sleep apnea)
  • take certain medicines called monoamine oxidase (MAO) inhibitors

Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.

ZEPOSIA may cause serious side effects, including:

  • Infections. ZEPOSIA can increase your risk of serious infections that can be life-threatening and cause death. ZEPOSIA lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 months of stopping treatment. Your healthcare provider may do a blood test of your white blood cells before you start taking ZEPOSIA.

    Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:

    • fever
    • feeling very tired
    • flu-like symptoms
    • cough
    • painful and frequent urination (signs of a urinary tract infection)
    • rash
    • headache with fever, neck stiffness, sensitivity to light, nausea, or confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

    Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.

  • Slow heart rate (also known as bradyarrhythmia) when you start taking ZEPOSIA. ZEPOSIA may cause your heart rate to temporarily slow down, especially during the first 8 days. You will have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of ZEPOSIA.

    Call your healthcare provider if you experience the following symptoms of slow heart rate:

    • dizziness
    • lightheadedness
    • feeling like your heart is beating slowly or skipping beats
    • shortness of breath
    • confusion
    • chest pain
    • tiredness

    Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.

Continue reading for additional possible serious side effects of ZEPOSIA.

Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you:

  • have a fever or infection, or are unable to fight infections due to a disease, or take or have taken medicines that lower your immune system
  • received a vaccine in the past 30 days or are scheduled to receive a vaccine. ZEPOSIA may cause vaccines to be less effective
  • before you start ZEPOSIA, your healthcare provider may give you a chickenpox (Varicella Zoster Virus) vaccine if you have not had one before
  • have had chickenpox or have received the vaccine for chickenpox. Your healthcare provider may do a blood test for the chickenpox virus. You may need to get the full course of the vaccine and wait 1 month before taking ZEPOSIA
  • have a slow heart rate
  • have an irregular or abnormal heartbeat (arrhythmia)
  • have a history of stroke
  • have or have had heart problems, including a heart attack or chest pain
  • have high blood pressure
  • have liver problems
  • have breathing problems, including during your sleep
  • have eye problems, especially an inflammation of the eye called uveitis
  • have diabetes
  • are or plan to become pregnant or if you become pregnant within 3 months after you stop taking ZEPOSIA. ZEPOSIA may harm your unborn baby. If you are a female who can become pregnant, talk to your healthcare provider about what birth control method is right for you during your treatment with ZEPOSIA and for 3 months after you stop taking ZEPOSIA
  • are breastfeeding or plan to breastfeed. It is not known if ZEPOSIA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ZEPOSIA.

Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using ZEPOSIA with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:

  • medicines that affect your immune system, such as alemtuzumab
  • medicines to control your heart rhythm (antiarrhythmics), or heartbeat
  • CYP2C8 inducers such as rifampin
  • CYP2C8 inhibitors such as gemfibrozil (medicine to treat high fat in your blood)
  • opioids (pain medicine), medicines to treat depression, and medicines to treat Parkinson’s disease
  • medicines to control your heart rate and blood pressure (beta blocker medicines and calcium channel blocker medicines)

You should not receive live vaccines during treatment with ZEPOSIA, for at least 1 month before taking ZEPOSIA and for 3 months after you stop taking ZEPOSIA. Vaccines may not work as well when given during treatment with ZEPOSIA.

ZEPOSIA can cause serious side effects, including:

  • liver problems. Your healthcare provider will do blood tests to check your liver before you start taking ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
    • unexplained nausea
    • vomiting
    • stomach area (abdominal) pain
    • tiredness
    • loss of appetite
    • yellowing of the whites of your eyes or skin
    • dark colored urine
  • increased blood pressure. Your healthcare provider should check your blood pressure during treatment with ZEPOSIA. A sudden, severe increase in blood pressure (hypertensive crisis) can happen when you eat certain foods that contain high levels of tyramine.
  • breathing problems. Some people who take ZEPOSIA have shortness of breath. Call your healthcare provider right away if you have new or worsening breathing problems.
  • a problem with your vision called macular edema. Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis. Your healthcare provider should test your vision before you start taking ZEPOSIA if you are at higher risk for macular edema or any time you notice vision changes during treatment with ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
    • blurriness or shadows in the center of your vision
    • sensitivity to light
    • a blind spot in the center of your vision
    • unusually colored vision
  • swelling and narrowing of the blood vessels in your brain. Posterior Reversible Encephalopathy Syndrome (PRES) is a rare condition that has happened with ZEPOSIA and with drugs in the same class. Symptoms of PRES usually get better when you stop taking ZEPOSIA. If left untreated, it may lead to stroke. Your healthcare provider will do a test if you have any symptoms of PRES. Call your healthcare provider right away if you have any of the following symptoms:
    • sudden severe headache
    • sudden confusion
    • sudden loss of vision or other changes in your vision
    • seizure
  • severe worsening of multiple sclerosis (MS) after stopping ZEPOSIA. When ZEPOSIA is stopped, symptoms of MS may return and become worse compared to before or during treatment. Always talk to your healthcare provider before you stop taking ZEPOSIA for any reason. Tell your healthcare provider if you have worsening symptoms of MS after stopping ZEPOSIA.

The most common side effects of ZEPOSIA can include:

  • upper respiratory tract infections
  • elevated liver enzymes
  • low blood pressure when you stand up (orthostatic hypotension)
  • painful and frequent urination (signs of urinary tract infection)
  • back pain
  • high blood pressure
  • headache

These are not all of the possible side effects of ZEPOSIA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATIONS

Multiple Sclerosis (MS): ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Ulcerative Colitis (UC): ZEPOSIA is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.

It is not known if ZEPOSIA is safe and effective in children.

Please see full Prescribing Information and Medication Guide.

Back to top

Important Safety Information

Expand

+

Do not take ZEPOSIA if you:

  • have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months
  • have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker
  • have untreated, severe breathing problems during your sleep (sleep apnea)

This website is best viewed using the vertical display on your mobile device.

This website is best viewed using the horizontal display on your tablet device.